Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PORTRAY: MA09-hRPE for Geographic Atrophy in AMD
NCT02563782Phase 2Withdrawn
- Sponsor
- Astellas Institute for Regenerative Medicine
- Start
- Aug 2015
- Primary completion
- May 2017
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ASP7317 in geographic atrophy (GA) (2 arms), sponsored by Astellas Institute for Regenerative Medicine. Primary endpoint: Number of subjects with evidence of graft failure or rejection at 18 months. Planned start Aug 2015; status: withdrawn.
02
Drugs
ASP7317
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT02563782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02563782.